| Unsubscribe |
Hi there,
I am writing to let you know that your 60% MarketBeat discount offer is set to expire in less than 12 hours.
More than one hundred of your fellow MarketBeat newsletter subscribers have upgraded to MarketBeat All Access in the last week (and they have gotten a great deal on their annual membership). Unfortunately, you haven't taken action yet.
We are making MarketBeat All Access available for 60% off (just $99 for the year) for anyone that registers by 11:59 PM Pacific Time. That's a savings of $150.00 on your annual subscription.
Click Here to Upgrade Your Account to MarketBeat All Access
If you aren't completely satisfied with your MarketBeat All Access membership, just send a note to our South Dakota-based customer support team at contact@analystratings.net. You are eligible for a full refund within your first 30 days of membership and we process all refunds within one business day.
Why Upgrade to MarketBeat All Access?
- Access Award-Winning Research Tools - MarketBeat All Access offers a full suite of modern stock research and portfolio monitoring tools backed by comprehensive financial datasets that you can't get anywhere else. MarketBeat tracks more than two million market events and news stories each year, creating an unrivaled ability to provide accurate, complete, and up-to-the-minute financial information.
- Cut Through the Noise - Equities research analysts issue more than 175,000 distinct "Buy" and "Sell" recommendations each year. After tracking the ROI of following analyst recommendations for nearly a decade, we know which analysts you should pay attention to and which you can safely ignore. With your All Access subscription, you'll get access to our list of top-rated and most-accurate brokers as well as their most recent "Buy" and "Sell" recommendations.
- Real-Time Data for Timely Trades - You will be among the first to receive your daily newsletter and instant email and SMS alerts for important market events. You won't need to scour through dozens of different websites to find news relevant to your stocks. Use MarketBeat All Access to get ratings, earnings, dividends, insider trades, and headlines delivered to your inbox automatically, every day.
Save 60% on MarketBeat All Access
Matthew Paulson
MarketBeat
P.S. This offer is only available through 11:59 PM Pacific tonight. Take action now!
Register Here for MarketBeat All Access
Why Johnson & Johnson’s Earnings Dip Looks Like a Buying Opportunity
Reported by Thomas Hughes. Publication Date: 7/15/2026.
Key Points
- Johnson & Johnson's post-earnings pullback of nearly 10% is viewed as a buying opportunity given strong fundamentals and rising analyst price targets.
- The company posted $25.31 billion in quarterly revenue and raised full-year guidance, projecting revenue will surpass $100 billion for the first time.
- Key risks include ongoing talc litigation and the patent cliff, though analysts believe the pipeline and planned orthopedics spin-off support continued growth.
- Special Report: Forget SpaceX. Buy the company Musk can't replace.
Johnson & Johnson (NYSE: JNJ) is an elite income investment because of its Dividend King status, healthy balance sheet, and exceptionally strong defensive business model. Key strengths include its product portfolio and pipeline, which are generating multiple catalysts at once in 2026.
A wave of approvals, expanded uses, and pipeline progress points to sustained growth, robust cash flow, and safe capital returns well into the future. That is why the mid-July price pullback, triggered by the earnings results and guidance, looks like a textbook entry point.
JNJ Pulls Back to Buy Zone
Where to Put $100 Before Trump's New Tech Law Rolls Out (Ad)
The Financial Times says a new tech law puts America 'on the verge of a financial revolution.' Yahoo Finance estimates it could unlock $400 trillion - but analyst Jeff Brown, who was consulted by Congressional offices on the legislation, believes the real figure could reach $2.6 quadrillion.
Brown says this shift will pour onto a new type of investment exchange - and he's showing investors how to position themselves starting with just $100.
Click here to see how Jeff Brown says to claim your stakeJNJ hit a peak ahead of the earnings release, suggesting a pullback was possible. The stock fell about 2% after the report and is now on pace for nearly a 10% pullback, which would represent a meaningful discount to the recent high. Even so, further downside appears unlikely.
Likely buyers on the dip include institutional investors, which own more than 60% of the stock and have been accumulating shares, as well as analysts, whose trends reflect growing confidence in an already fundamentally stable company.
Analyst trends include increased coverage compared with last year, firmer sentiment, a 74% buy-side bias to the Moderate Buy rating, and an uptrend in price targets. Consensus remains a sticking point, with fair value near the early July highs, but the trend matters and points toward the high end of $300 and fresh all-time highs. A move to new highs would be significant for chart watchers, as it would signal trend continuation, with near-term targets at $300 and longer-term targets in the $350 range.
Analyst commentary after the release focused on the beat relative to the high bar that had been set. Strength in the pharmaceutical pipeline and underlying health in MedTech were also highlighted. Importantly, the market views JNJ as having moved past its patent cliff and now being on track for sustainable growth, cash flow, and capital returns.
Capital returns include buybacks, but they are opportunistic and often not enough to offset dilution; the dividend is far more important. The dividend yields an above-average 2.1% and has grown at a mid-single-digit compound annual growth rate in recent years. The likely outcome is that JNJ will continue raising its dividend annually well into the future.
Johnson & Johnson’s Strength Driven by Diversified Portfolio
Johnson & Johnson had a strong quarter, underscoring the strength of its repositioning efforts and portfolio. The company’s $25.31 billion in net revenue increased 6.8% year-over-year (YOY), 100 basis points (bps) better than expected, supported by strength in U.S. and international markets across the Innovative Medicine and MedTech portfolios. There were scattered weaknesses within each segment tied to legacy products, but each was offset by strength elsewhere. Key details include roughly half a dozen new approvals and about a dozen positive pipeline updates.
Margin news was also positive. The company faced margin pressure but was able to offset it to a large degree. Bottom-line results included $2.90 in adjusted earnings per share (EPS), up 4.7% YOY and a nickel ahead of consensus, as well as $8.7 billion in free cash flow (FCF), more than enough to support balance sheet health while continuing to invest and return capital to investors.
Looking ahead, the company expects those strengths to continue and has raised guidance accordingly. The new full-year targets were increased by 30 bps at the midpoint, with expectations for 7.3% top-line growth and $11.68 in adjusted earnings, well above the consensus estimate. Investors should also note that JNJ expects revenue to surpass the $100 billion mark for the first time in its history, a psychological milestone for institutional investors.
JNJ: Low Risk, High Reward
Johnson & Johnson’s primary risks include its patent cliff and ongoing talc litigation. The talc litigation stems from decades of lawsuits alleging that the company's talc-based products—most notably its baby powder—were contaminated with asbestos and caused ovarian cancer and mesothelioma.
The patent cliff appears to be easing, with approvals and pipeline momentum building, leaving talc as the main hurdle for investors. The company continues to face thousands of individual claims despite its attempts to settle. That leaves it exposed to cash-draining adverse decisions that could reduce investment capital and capacity for capital returns. What the market gets wrong is that talc is not a company-ending threat, but rather a slow drain on capital that may or may not worsen.
Catalysts include the planned spin-off of the company's orthopedics business. Analysts view it as a move that could unlock valuation by trimming lower-margin, slower-growing businesses in favor of higher-performing ones. The resulting company will be a pharma and medtech powerhouse with strong franchises in oncology, cardiology, and potentially robotics. The OTTAVA robotic system is on track for approval as soon as later this year, setting the stage for it to gain share against competitors like Intuitive Surgical (NASDAQ: ISRG).
Why Wall Street Suddenly Sees SpaceX as an AI Company
Reported by Sam Quirke. Publication Date: 7/19/2026.
Key Points
- SpaceX shares have fallen about 40% since their June 12 IPO and now trade below the $135 listing price.
- Wall Street is increasingly framing SpaceX's Starlink network as AI infrastructure rather than just a space or satellite business.
- SpaceX's first public earnings report on Aug. 6 is seen as pivotal for validating the AI narrative amid mixed analyst price targets.
- Special Report: Forget SpaceX. Buy the company Musk can't replace.
When SpaceX (NASDAQ: SPCX) went public just over a month ago, on June 12, it did so as the most hotly anticipated listing in years, and unmistakably as a space company. Rockets, satellites, and Mars ambitions drove the story. But barely a month into its life on the public markets, a different narrative is taking hold on Wall Street, and it has far more to do with artificial intelligence (AI) than with space travel.
The timing is notable because the stock itself has had a rough start. After hitting a post-IPO high in the sessions following its debut, SpaceX shares have slumped about 40% and are now trading below the $135 price at which they listed.
Where to Put $100 Before Trump's New Tech Law Rolls Out (Ad)
The Financial Times says a new tech law puts America 'on the verge of a financial revolution.' Yahoo Finance estimates it could unlock $400 trillion - but analyst Jeff Brown, who was consulted by Congressional offices on the legislation, believes the real figure could reach $2.6 quadrillion.
Brown says this shift will pour onto a new type of investment exchange - and he's showing investors how to position themselves starting with just $100.
Click here to see how Jeff Brown says to claim your stakeFor a company that generated so much excitement on the way to market, dipping below the IPO price within the first few weeks is not a great look. Yet beneath that disappointing price action, the emerging investment case may be more compelling than the chart suggests.
Why the AI Narrative Is Taking Over
The core of the argument is Starlink, SpaceX's satellite internet network. On the surface, it's a connectivity business, beaming broadband to homes, vehicles, and remote corners of the planet. But increasingly, investors are recognizing that a global, low-latency connectivity network is exactly the kind of infrastructure the AI era is likely to depend on.
As AI systems become more embedded in everyday devices, vehicles, and industrial applications, the need for reliable connectivity to move data back and forth grows enormously. Starlink is one of the few networks capable of providing that coverage at scale.
Bulls argue this could make SpaceX something like an AI infrastructure landlord, with its network and vertical integration allowing it to control data movement and potentially support entirely new compute products over time.
This is a view that Wedbush's Dan Ives has been vocal about for some time. He argues that SpaceX should be seen as much more of a data and AI play than a traditional space company, pointing to the strategic value of its network and the growing data demands flowing through it. If that framing gains wider acceptance, it would fundamentally change the lens through which the company is valued to the upside.
The Speculative Upside, and the Very Real Risks
Beyond connectivity, there's an even more ambitious element to the thesis. There has been growing discussion around the potential for data centers in space, using solar power and natural cooling to run compute-intensive AI workloads outside the constraints of terrestrial infrastructure.
Tied to this is the Terafab semiconductor project, which Oppenheimer recently described as “critical” to SpaceX's future valuation, while also cautioning that it remains speculative and carries real execution risk.
That tension sits at the heart of the debate. The upside case is enormous, but it rests on ambitious projects that are far from proven, and the company is burning through significant cash to pursue them. Bears make a fair point that the current valuation already implies extraordinary growth, with no guarantee that the vast AI opportunity translates cleanly into durable, high-margin profits.
What the Analysts Are Saying
Despite that rough start, the early analyst coverage suggests the bulls currently outnumber the bears. While Piper Sandler did initiate coverage this week with a cautious Neutral rating, that was a rare outlier versus the likes of Evercore, which gave the stock a Buy rating, one of many in a run of recent bullish analyst calls.
The price targets in some of these recent updates are also hard to ignore, with many clustered around $250. From the current level near $130, that implies close to 100% upside. Targets like that suggest at least some analysts believe the recent weakness reflects a serious disconnect between the share price and the company's longer-term potential. If the AI infrastructure narrative takes hold, the current price could look like an entry point in hindsight.
A High-Stakes First Report Awaits
All of this makes SpaceX's first public earnings report, due on Aug. 6, a pivotal moment. As a newly listed company with no track record of reporting to public markets, this first look under the hood will carry enormous weight in shaping how investors think about the story.
The key will be any commentary that supports the AI infrastructure framing, particularly around Starlink's growth and how management chooses to position the business. Lean into the AI narrative convincingly, and the bulls calling for a doubling of the stock will have real ammunition.
Fall back on a more pie-in-the-sky space story, and that 40% sell-off may prove less an entry point and more a warning. Either way, Aug. 6 should be firmly circled on every investor's calendar.
If you have questions or concerns about your newsletter, please feel free to contact our South Dakota based support team at contact@marketbeat.com.
If you no longer wish to receive email from The Early Bird, you can unsubscribe.
© 2006-2026 MarketBeat Media, LLC. All rights reserved.
345 North Reid Place, Sixth Floor, Sioux Falls, S.D. 57103-7078. U.S.A..
Post a Comment
0Comments